During the last session, Allogene Therapeutics Inc (NASDAQ:ALLO)’s traded shares were 2.77 million, with the beta value of the company hitting 0.87. At the end of the trading day, the stock’s price was $2.86, reflecting an intraday loss of -6.09% or -$0.18. The 52-week high for the ALLO share is $6.89, that puts it down -140.91 from that peak though still a striking 22.03% gain since the share price plummeted to a 52-week low of $2.23. The company’s market capitalization is $482.75M, and the average trade volume was 2.28 million shares over the past three months.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Allogene Therapeutics Inc (ALLO) registered a -6.09% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.09% in intraday trading to $2.86, hitting a weekly high. The stock’s 5-day price performance is -17.49%, and it has moved by -32.19% in 30 days. Based on these gigs, the overall price performance for the year is -49.02%.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Statistics show that Allogene Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Allogene Therapeutics Inc (ALLO) shares have gone up 2.70% during the last six months, with a year-to-date growth rate more than the industry average at 15.92% against 12.90. In the rating firms’ projections, revenue will decrease -57.90% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10k as predicted by 10 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 10k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 52k and 44k respectively. In this case, analysts expect current quarter sales to shrink by -80.80% and then drop by -77.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 22.18%. While earnings are projected to return 21.14% in 2024, the next five years will return 1.00% per annum.
ALLO Dividends
Allogene Therapeutics Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
